Apixaban Perioperative Management
Stop apixaban 24 hours before low-bleeding-risk surgery (skip 1 dose) and 48 hours before high-bleeding-risk surgery (skip 2 doses) in patients with normal renal function. This approach, validated in the PAUSE trial with over 1,200 apixaban patients, resulted in extremely low rates of both thromboembolism (0.16%) and major bleeding (1.35%) 1, 2.
Preoperative Interruption Strategy
The timing of apixaban discontinuation depends on two critical factors: surgical bleeding risk and renal function.
For Normal Renal Function (CrCl ≥50 mL/min):
Low-to-moderate bleeding risk procedures:
- Stop apixaban 1 day before surgery (24 hours)
- This means skipping 1 dose before the procedure
- Examples: arthroscopy, dental extractions, colonoscopy with biopsy, laparoscopic cholecystectomy 1, 3
High bleeding risk procedures:
- Stop apixaban 2 days before surgery (48 hours)
- This means skipping 2 doses before the procedure
- Examples: major abdominal surgery, cardiac surgery, spinal surgery, neuraxial anesthesia, procedures with anastomosis 1, 3
For Impaired Renal Function (CrCl <30 mL/min):
Low-to-moderate bleeding risk:
- Stop apixaban 36 hours before surgery 4
High bleeding risk:
- Stop apixaban 48 hours before surgery 4
The FDA label confirms this approach: apixaban should be discontinued at least 24 hours prior to low-risk procedures and at least 48 hours prior to moderate or high-risk procedures 5.
Key Principles
No bridging anticoagulation is needed. Unlike warfarin management, the rapid offset of apixaban (half-life 7-8 hours) eliminates the need for heparin bridging during the interruption period 1, 2. The FDA explicitly states "bridging anticoagulation during the 24 to 48 hours after stopping apixaban and prior to the intervention is not generally required" 5.
Renal function matters less for apixaban than dabigatran. Apixaban has only 25% renal clearance, so renal impairment has minimal impact on timing compared to dabigatran (which requires 4-day interruption with CrCl <50 mL/min) 6.
Postoperative Resumption
Low bleeding risk surgery:
- Resume apixaban 24 hours after surgery at full dose (5 mg twice daily) 6
High bleeding risk surgery:
- Resume apixaban 48-72 hours after surgery once hemostasis is established 6
- Consider reduced dose (2.5 mg twice daily) for first 2-3 days in very high thrombotic risk patients, then increase to full dose 6
The 2024 AHA/ACC guidelines support this timing, emphasizing resumption only after adequate hemostasis 3.
Common Pitfalls to Avoid
Don't extend interruption unnecessarily. The older 2014 Canadian guidelines suggested 2-3 days for high-risk procedures 7, but the more recent 2022 CHEST guidelines and 2024 AHA/ACC guidelines based on PAUSE trial data demonstrate that 48 hours is sufficient 1, 3, 2.
Don't use bridging therapy. This increases bleeding risk without reducing thrombotic events 1, 2.
Don't forget drug interactions. Patients on combined P-gp and strong CYP3A4 inhibitors (ketoconazole, ritonavir) may need longer interruption periods due to prolonged apixaban half-life 5.
Don't resume too early after high-risk surgery. Premature resumption is the leading cause of postoperative bleeding complications. Wait for clinical evidence of hemostasis 6.
Minimal Risk Procedures
For truly minimal bleeding risk procedures (cataract surgery, minor dental work, skin biopsies), apixaban can be continued without interruption 1, 3. The bleeding at these sites is easily controlled and non-critical.
Evidence Quality
The PAUSE trial 2 represents the highest quality evidence for DOAC perioperative management—a prospective study of over 3,000 patients with standardized protocols showing excellent safety outcomes. The 2022 CHEST guidelines 1, 2 and 2024 AHA/ACC guidelines 3 both prioritize this evidence over older expert opinion-based recommendations.